RYAH Group (CSE: RYAH) announced the issuance of a failure-to-file cease trade order (‘’FFCTO”) from the Canadian Securities Exchange. Effective immediately, the order is on trading of RYAH Group’s subordinated voting shares listed on the Canadian Securities Exchange. According to the announcement, RYAH had requested a management cease trade order (‘’MCTO”) from the exchange in May, but the company intended to be in compliance with continuous disclosure obligations by the end of the two-month period on July 4, 2022. However, the company acknowledged that despite the best efforts of new management and RYAH’s auditors, there was not enough time to meet that deadline. “The company’s management and board of directors wish to inform its investors, partners, and service and goods suppliers that it will continue working diligently and rapidly to finalize the audit and to file the needed documents with the authorities,” the announcement stated. “As part of its filing commitment, the company will also need to file the March 31, 2022, quarterly financial statements, MD&A and CEO and CFO certificates. The company’s management and other insiders will continue to respect the insider trading prohibitions under securities legislation before entering into any transaction involving securities of the company in default. The company will also endeavor to issue regular news releases to keep the investing public apprised of the situation and the evolution of its audit and filing efforts.”
To view the full press release, visit https://ibn.fm/yPxkf
About RYAH Group Inc.
RYAH is a big data and technology company enabling valuable AI-powered predictive analytics of the efficacy of plant-based medicines and other nutraceuticals administered through its range of innovative IoT-connected medical devices including inhalers, patches and pens. RYAH’s robust big data platform, the only one of its kind in this space, aggregates and analyzes HIPAA-compliant patient data, helping doctors and patients personalize treatments, control dosages, and better predict and monitor outcomes. Beyond specific medical uses, RYAH supports the use of a variety of nutraceuticals by users for wellness purposes, including personal enjoyment, i.e., recreational use. The collection and analyses of objective and subjective usage data, along with data derived through natural language processing of various scientific and other relevant literatures, will enable highly valuable insights for a wide variety of stakeholders, starting with the users themselves and extending to clinicians, medical scientists, insurance providers, dispensaries, licensed growers, producers, pharmaceutical producers and more. Through the above, a relentless focus on innovation and a track record of developing win-win collaborative partnerships within relevant industries, RYAH is continuously building a unique and highly valuable IP portfolio and big data assets ready to be monetized. For more information about the company, please visit www.RyahGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
